first patient treated witH ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes Atrogi announced today that the first patient has been enrolled in a Phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel ß2 adrenoceptor agonist with a unique mechanism of action for the …
Atrogi announces first patient treated with Adrenoceptor agonist Read More »
Along side leading Big Pharma companies Atrogi participated in the 58th European Association for the Study of Diabetes (EASD) Annual meeting in Stockholm!
Atrogi is developing novel compounds and treatments of metabolic disorders and a robust patent portfolio has been generated to develop the commercial asset and increase value. Several patents have already been granted; here are two of the more recent from June and August. US 11,357,757Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycemia US 11,427,539 Beta-hydroxy heterocyclic …
Atrogi welcomes Anders Ekblom as the new chairman of the board. Anders Ekblom has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry, with global experience delivering products, projects, productivity and change management. He is currently Chairman/Non-Executive Board member of several biotech companies namely AnaMar AB, Alligator Bioscience AB, …
Atrogi is one of a few companies to be selected for a prestigious grant from Eurostars, an initiative of the European Commission that promotes research, and the intergovernmental innovation network EUREKA. The application was done in consortium with Stockholm University, Maastricht University, the Latvian Institute of Organic Synthesis and Excellerate Bioscience. The grant awarded is …
Atrogi receives Eurostars grant to develop obesity project Read More »
Diabetes company Atrogi has completed a SEK 90 million rights issue for the continued in-house development of a new class of diabetes drug The Swedish diabetes company Atrogi has recently completed a rights issue, raising approximately SEK 90 million. Among the anchor investors is South Korea’s largest venture capital company Korea Investment Partners (KIP). “We …
Atrogi has completed a SEK 90 million rights issue Read More »
Atrogi participated in BIO-Europe 2017 in Berlin, which is the largest partnering meeting in Europe. The purpose was to present our type 2 diabetes project to pharmaceutical companies. At the meeting Atrogi met with several of the largest companies that are working in the diabetes area. The response was overwhelming and Atrogi will follow up the requests for information.
This very prestigeful grant from the SWElifes accelerator program was received in fierce competition with other applicants.
